Pharmacy and Poisons Board offices along Lenana Road in Nairobi. The building was officially opened in 2005 by the Minister of Health at the time, Hon. Charity Ngilu.
Pharmacovigilance department came out to the Kenyan public on the 9th of June 2009 when a formal launch of the Pharmacovigilance System in Kenya took place at the Panafric Hotel in Nairobi.
National Quality Control Laboratory. The quality of a drug is one of the criteria for market approval. Quality assurance covers all activities aimed at ensuring that consumers and patients receive a product that meets established specifications and standards of quality, safety an efficacy.
Ministry of Health HQ
Pharmacy and Poisons Board is under the Ministry of Health whose HQ are at Afya House, Bishop Road, Nairobi
The Pharmacy and Poisons Board has various guidelines that explain how services are delivered. The guidelines can be downloaded from this site.
DHCP B Immune Recall - Pdf
Suspected Adverse Drug Reaction Reporting Form (Yellow Form) - Pdf
Suspected Lack of Efficacy: Tocinox 5 i.u./mL injections - Pdf
Pharmacy and Poisons Board Supplement in the Newspapers - Pdf
Voluntary Product Recall- certain batches of Typhim Vi (Typhoid vaccine) by Sanofi Pasteur - Pdf
Falsified Nilzan Plus with Cobalt Liquid (Veterinary product) - Pdf
Withdrawal of Xigris (Drotrecogin Alfa) from the market - Pdf
Counterfeit Postinor - Doc
Illegal Distribution of FUZOL - Doc
Complaints Dextrose - Doc
Poor Quality FLAGIMED - Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 1: Community -Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 2-3: Primary Care -Doc
Clinical Guidelines for Management and Referral of Common Conditions at Level 4-6: Hospitals - Doc
Poor Quality Paracetamol - Doc
Poor Quality Benzylpenicillin - Doc
National Guidelines for the Diagnosis, Treatment and Prevention of Malaria in Kenya - Doc
Photosensitivity reactions- reminder to all health-care professionals of the risk of photosensitivity reactions with a number of topical and systematic medicines - Doc
Voluntary Recall of Polaramine Expectorant - Doc
Suspension of Market Authorization for Rosiglitazone and Rosiglitazone-containing products - Doc
Suspension of Market Authorization for Sibutramine and Sibutramine-containing products - Doc
Kenya Becomes 98th Full Member of the WHO Programme for International Drug Monitoring - Doc
Updated recommendations concerning the interaction with calcium-containing products Ceftriaxone- Doc